Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-101903 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-101905 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-101906 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-101907 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-101908 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-101909 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-20-101445 Act: 34 Size: 237 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001047469-20-004734 Act: 33 Size: 513 KB 网页链接
$Nabriva Therapeutics(NBRV)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001104659-20-101436 Act: 33 Size: 2 MB 网页链接
$Nabriva Therapeutics(NBRV)$ 内部交易: 2020-08-20,Director,Broom Colin MD ,卖出,11064普通股, $0.65